Forman Stephen J. 4
4 · LIXTE BIOTECHNOLOGY HOLDINGS, INC. · Filed Jan 22, 2025
Insider Transaction Report
Form 4
Forman Stephen J.
Director
Transactions
- Award
Options to Purchase Common Stock
2025-01-20+3,030→ 3,030 totalExercise: $2.33From: 2025-01-20Exp: 2030-01-20→ Common (3,030 underlying)
Holdings
- 3,018
Options to Purchase Common Stock
Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (3,018 underlying) - 10,000
Options to Purchase Common Stock
Exercise: $30.30From: 2021-06-30Exp: 2026-06-30→ Common (10,000 underlying) - 833
Options to Purchase Common Stock
Exercise: $66.00From: 2019-05-22Exp: 2024-05-22→ Common (833 underlying) - 1,667(indirect: By Trust)
Warrants to Purchase Common Stock
Exercise: $60.00From: 2018-12-07Exp: 2022-12-07→ Common (1,667 underlying) - 10,000
Options to Purchase Common Stock
Exercise: $7.45From: 2022-06-30Exp: 2027-06-30→ Common (10,000 underlying) - 3,858
Options to Purchase Common Stock
Exercise: $1.30From: 2024-09-30Exp: 2029-09-30→ Common (3,858 underlying) - 10,000
Options to Purchase Common Stock
Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (10,000 underlying) - 5,000
Options to Purchase Common Stock
Exercise: $32.10From: 2021-01-06Exp: 2026-01-06→ Common (5,000 underlying) - 10,000
Options to Purchase Common Stock
Exercise: $5.88From: 2023-06-30Exp: 2028-06-30→ Common (10,000 underlying) - 2,105(indirect: By Trust)
Warrants to Purchase Common Stock
Exercise: $57.00From: 2018-12-07Exp: 2022-12-07→ Common (2,105 underlying) - 833
Options to Purchase Common Stock
Exercise: $9.00From: 2017-10-16Exp: 2022-10-16→ Common (833 underlying)
Footnotes (1)
- [F1]Effective January 20, 2025, the reporting person was granted stock options to purchase an aggregate of 3,030 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.